Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/22839
Full metadata record
DC FieldValueLanguage
dc.contributor.authorLau, David K-
dc.contributor.authorBurge, Matthew-
dc.contributor.authorRoy, Amitesh-
dc.contributor.authorChau, Ian-
dc.contributor.authorHaller, Daniel G-
dc.contributor.authorShapiro, Jeremy D-
dc.contributor.authorPeeters, Marc-
dc.contributor.authorPavlakis, Nick-
dc.contributor.authorKarapetis, Christos S-
dc.contributor.authorTebbutt, Niall C-
dc.contributor.authorSegelov, Eva-
dc.contributor.authorPrice, Timothy J-
dc.date2020-03-18-
dc.date.accessioned2020-03-23T22:10:38Z-
dc.date.available2020-03-23T22:10:38Z-
dc.date.issued2020-04-
dc.identifier.citationExpert Review of Anticancer Therapy 2020; 20(4): 251-270en
dc.identifier.urihttps://ahro.austin.org.au/austinjspui/handle/1/22839-
dc.description.abstractIntroduction: Outcomes in metastatic colorectal cancer are improving, due to the tailoring of therapy enabled by better understanding of clinical behaviour according to molecular subtype.Areas covered: A review of the literature and recent conference presentations was undertaken on the topic of systemic treatment of metastatic colorectal cancer. This review summarises expert discussion of the current evidence for therapies in metastatic colorectal cancer (mCRC) based on molecular subgrouping.Expert opinion: EGFR-targeted and VEGF-targeted antibodies are now routinely incorporated into treatment strategies for mCRC. EGFR-targeted antibodies are restricted to patients with extended RAS wild-type profiles, with evidence that they should be further restricted to patients with left-sided tumours. Clinically distinct treatment pathways based on tumour RAS, BRAF, HER2 and MMR status, are now clinically applicable. Evidence suggests therapy for additional subgroups will soon be defined; the most advanced being for patients with KRAS G12C mutation and gene TRK fusion defects.en
dc.language.isoeng-
dc.subjectBRAFen
dc.subjectMSIen
dc.subjectRASen
dc.subjectchemotherapyen
dc.subjectcolorectalen
dc.subjectconsensusen
dc.subjectmetastaticen
dc.titleUpdate on optimal treatment for metastatic colorectal cancer from the AGITG expert meeting: ESMO Congress 2019.en
dc.typeJournal Articleen
dc.identifier.journaltitleExpert Review of Anticancer Therapyen
dc.identifier.affiliationGI and Lymphoma Unit, Royal Marsden NHS Foundation Trust, London and Surrey, United Kingdomen
dc.identifier.affiliationMedical Oncology, Flinders Centre for Innovation in Cancer, Bedford Park, Australiaen
dc.identifier.affiliationDepartment of Medical Oncology, Austin Health, Heidelberg, Victoria, Australiaen
dc.identifier.affiliationDept of Surgery, University of Melbourne, Melbourne, Australiaen
dc.identifier.affiliationMedical Oncology, Monash Medical Centre, Clayton, Australiaen
dc.identifier.affiliationMedical Oncology, The Queen Elizabeth Hospital, Woodville, Australiaen
dc.identifier.affiliationMedical Oncology, Flinders Medical Centre, Bedford Park, Australiaen
dc.identifier.affiliationAbramson Cancer Center at the Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USAen
dc.identifier.affiliationMedical Oncology, Royal Brisbane Hospital, Brisbane, Australiaen
dc.identifier.affiliationUniversity of Queensland, Brisbane, Australiaen
dc.identifier.affiliationMonash University, Melbourne, Australiaen
dc.identifier.affiliationMedical Oncology, Cabrini Medical Centre, Melbourne, Australiaen
dc.identifier.affiliationMedical Oncology, Royal North Shore Hospital, St Leonards, Australiaen
dc.identifier.affiliationSydney University, Camperdown, Sydney, Australiaen
dc.identifier.affiliationGI and Lymphoma Unit, Royal Marsden NHS Foundation Trust, London and Surrey, United Kingdom..en
dc.identifier.affiliationMedical Oncology, University Hospital Antwerp, Oncology, Edegem, Belgium..en
dc.identifier.doi10.1080/14737140.2020.1744439en
dc.type.contentTexten
dc.identifier.pubmedid32186929-
dc.type.austinJournal Article-
local.name.researcherLau, David K
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.cerifentitytypePublications-
item.fulltextNo Fulltext-
item.grantfulltextnone-
item.languageiso639-1en-
item.openairetypeJournal Article-
crisitem.author.deptOlivia Newton-John Cancer Research Institute-
crisitem.author.deptMedical Oncology-
crisitem.author.deptOlivia Newton-John Cancer Wellness and Research Centre-
Appears in Collections:Journal articles
Show simple item record

Page view(s)

16
checked on Mar 28, 2024

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.